Post-Authorization Activity Table for Tafinlar

The PAAT describes post-authorization activity for Tafinlar, a product which contains the medicinal ingredient dabrafenib (as dabrafenib mesylate). Based on Health Canada's review, the benefit/risk profile of Tafinlar is favourable as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Read more here.